open access

Vol 80, No 2 (2009)
ARTICLES
Get Citation

Expression of selected angiogenesis markers and modulators in pre-, peri- and postmenopausal women with ovarian cancer

Bartłomiej Barczyński, Alicja Ćwiklińska, Magdalena Mazurek, Wiesława Bednarek
Ginekol Pol 2009;80(2).

open access

Vol 80, No 2 (2009)
ARTICLES

Abstract

Summary Introduction: One of the most commonly assessed angiogenesis markers is microvessel density which is determined on the bases of specific endothelial antigen expression (CD34, CD105). Angiogenesis modulators include growth factors and their receptors (EGFR), proteases and their inhibitors, oncogenes and suppressor genes (p53). Objective: The aim of the study was to evaluate whether there are any differences in selected angiogenesis markers and modulators expressions in ovarian cancer patients with different menopause status. Material and methods: The study included 100 women, age 30-70, who underwent surgical treatment due to ovarian cancer. As far as their menopause status was concerned, the women were divided into three groups: pre-, peri-, and postmenopausal. Microvessel density was assessed on the basis of CD34 (MVDCD34) and CD105 (MVDCD105) expression. Additionally, tumor tissue p53 protein and EGFR expression were investigated. Active EGFR form in blood serum samples of cancer patients was assessed before the surgery. Results: Microvessel density, assessed on the basis of CD34 and CD105 expression, as well as p53 and EGFR expression were similar in all three groups of patients. Active EGFR serum concentration in women with ovarian cancer did not prove to be significantly different and did not depend on the menopause status. Conclusion: Intensity of the angiogenesis process does not depend on the menopausal status of women and is similar in pre-, peri- and postmenopausal patients.

Abstract

Summary Introduction: One of the most commonly assessed angiogenesis markers is microvessel density which is determined on the bases of specific endothelial antigen expression (CD34, CD105). Angiogenesis modulators include growth factors and their receptors (EGFR), proteases and their inhibitors, oncogenes and suppressor genes (p53). Objective: The aim of the study was to evaluate whether there are any differences in selected angiogenesis markers and modulators expressions in ovarian cancer patients with different menopause status. Material and methods: The study included 100 women, age 30-70, who underwent surgical treatment due to ovarian cancer. As far as their menopause status was concerned, the women were divided into three groups: pre-, peri-, and postmenopausal. Microvessel density was assessed on the basis of CD34 (MVDCD34) and CD105 (MVDCD105) expression. Additionally, tumor tissue p53 protein and EGFR expression were investigated. Active EGFR form in blood serum samples of cancer patients was assessed before the surgery. Results: Microvessel density, assessed on the basis of CD34 and CD105 expression, as well as p53 and EGFR expression were similar in all three groups of patients. Active EGFR serum concentration in women with ovarian cancer did not prove to be significantly different and did not depend on the menopause status. Conclusion: Intensity of the angiogenesis process does not depend on the menopausal status of women and is similar in pre-, peri- and postmenopausal patients.
Get Citation

Keywords

EGFR, p53, CD34, neovascularization - pathologic ovarian neoplasms, Receptor - Epidermal Growth Factor

About this article
Title

Expression of selected angiogenesis markers and modulators in pre-, peri- and postmenopausal women with ovarian cancer

Journal

Ginekologia Polska

Issue

Vol 80, No 2 (2009)

Bibliographic record

Ginekol Pol 2009;80(2).

Keywords

EGFR
p53
CD34
neovascularization - pathologic ovarian neoplasms
Receptor - Epidermal Growth Factor

Authors

Bartłomiej Barczyński
Alicja Ćwiklińska
Magdalena Mazurek
Wiesława Bednarek

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl